80 results about "Disulfiram" patented technology

There is described a composition comprising a therapeutically active imidazole, or a derivative thereof, and disulfiram, or a derivative thereof, for treating an infection contributed to or caused by multi-drug resistant bacterial species.

Methods, compositions of matter, and kits for treatment of breast cancer, and in particular for inflammatory breast cancer, in a patient are disclosed. The methods can include administering a redox modulating agent to the patient. The redox modulating agent can be disulfiram.

The present invention provides an implantable composition which contains disulfiram, an anti-inflammatory agent, and optionally a pharmaceutically acceptable carrier. Methods of making the implants, and methods of using the implants to treat alcoholism and opioid dependency are also disclosed.

The invention relates to an antitumor drug combination and a preparation and application thereof. The drug combination comprises a tumor angiogenesis inhibitor compound and disulfiram. Weight ratio ofthe angiogenesis inhibitor compound to disulfiram is (1-15): (1-20). By combination of the tumor angiogenesis inhibitor compound and disulfiram for medication, the antitumor drug combination has thefunction of remarkably raising anticancer effect in comparison with any single ingredient. In addition, tumor inhibiting rate is raised by 20% and above. The data is a great progress in the research on cancer treatment. In the inventor's first research, it is found that the combination of the angiogenesis inhibitor and disulfiram at a specific ratio has a remarkable synergistic effect and the drugcombination has a good clinical application prospect.

The invention provides a polyester material supported disulfiram nanoparticle, which is prepared from the following components: 1-20 parts by weight of disulfiram or derivatives thereof, 20-95 parts by weight of a polyethylene glycol-polyester segmented copolymer and 5-80 parts by weight of polycaprolactone. According to the disulfiram nanoparticle designed by the invention, a hydrophobic core, provided by polycaprolactone, is stably encapsulated inside the disulfiram, and the polyethylene glycol-polyester segmented copolymer is modified on the surface, so as to guarantee the solubility and the long-circulation capacity of the disulfiram nanoparticle. The application also provides application of the disulfiram nanoparticle on treating tumors.

The invention relates to a disulfiram implant and a preparation method thereof. The disulfiram medicinal composition can be slowly and stably released in a human body, and the disulfiram implant comprises 60-80 parts of disulfiram and 20-40 parts of a biodegradable high polymer material. The disulfiram implant can be injected and implanted into the human body, and patients suffering from alcohol dependence can be treated so as to avoid repeated drinking. The therapeutic concentration can be maintained for a long time after administration, a first-pass effect is avoided, the bioavailability is improved, the compliance of the patients is improved, and the clinical requirements of the patients can be met.

The invention relates to an application of disulfiram to preparation of a medicine for preventing and treating NLRP3 inflammasome related diseases. Research finds that the disulfiram can effectively inhibit activation of NLRP3 inflammasome and inhibit maturation and secretion of inflammatory activation signal molecules Caspase-1 P20 and inflammatory cytokine IL-1beta, has a good prevention and treatment effect on NLRP3 inflammasome related diseases, and particularly has a remarkable prevention and treatment effect on peritonitis and gouty arthritis.

The invention relates to the technical field of medicines, and especially relates to a preparation method and application of a disulfiram-loaded nano-emulsion in-situ gel. The preparation method comprises the following steps: (1) mixing an oil phase, an emulsifier and a co-emulsifier, adding polyethylene glycol-modified phospholipid, and uniformly mixing to obtain a first mixed solution; (2) adding disulfiram into the first mixed solution, and obtaining a second mixed solution after the disulfiram is completely dissolved; and (3) adding ultrapure water containing an in-situ gel agent into thenano-emulsion, and carrying out self-assembly to obtain the disulfiram-loaded nano-emulsion in-situ gel. According to the disulfiram-loaded nanoemulsion in-situ gel, the solubility of disulfiram is remarkably improved, an ideal slow release effect is achieved, the in-vivo stability of disulfiram is improved, high safety is achieved, and the characteristic of remarkable brain enrichment during nasal administration is achieved.

The invention belongs to the technical field of medicine, and specifically relates to mycobacterium tuberculosis resisting compounds, and applications thereof. The compounds comprise pyrrolidine dithiocarbamate (PDTC), diethyl dithiocarbamate (DETC) and disulfiram. The compounds have effective in vitro effects in inhibiting and killing mycobacterium tuberculosis. The compounds can be combined with first-line antituberculosis drugs pyrazinamide and rifampicin, and assist in improving the in vitro antibacterial activities of pyrazinamide, and pyrazinamide plus rifampicin. The compounds provided by the invention can effectively acts upon tuberculosis mycobacterium in growing phases and stationary phases. Mycobacterium tuberculosis resisting activities of the compounds can be presented. The compounds can be used in the treatment of drug-sensitive tuberculosis and multi-drug-resistant tuberculosis, and further can be applied in preparations of novel mycobacterium tuberculosis resisting medicines.

The invention belongs to the technical field of medicines, relates to disulfiram in-situ-forming gel eye drops as well as preparation and application thereof, in particular to in-situ-forming gel eyedrops which are treated based on a solid dispersion technology and prepared from disulfiram. The disulfiram in-situ-forming gel eye drops are prepared from a main drug, a solid dispersion matrix, an in-situ-forming gel matrix, a bacteriostatic agent, a pH value regulator, a gelation temperature regulator, an osmotic pressure regulator and injection water, wherein the main drug is the disulfiram; the solid dispersion matrix is one or more of HPMC, P407, P188 and PVP; the pH value regulator is borate and has the concentration of 0.001-0.05 percent; and the gel matrix is one or more of the P188 and the P407. The disulfiram in-situ-forming gel eye drops provided by the invention have the efficacy of preventing and treating cataract. According to the preparation, the solid dispersion technologyimproves the solubility and the permeability of indissolvable drugs, and an in-situ-forming gel technology prolongs the corneal retension time of the drugs. The eye drops improve the efficacy of thedisulfiram and have wide development prospect.